JPWO2020154268A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020154268A5 JPWO2020154268A5 JP2021543226A JP2021543226A JPWO2020154268A5 JP WO2020154268 A5 JPWO2020154268 A5 JP WO2020154268A5 JP 2021543226 A JP2021543226 A JP 2021543226A JP 2021543226 A JP2021543226 A JP 2021543226A JP WO2020154268 A5 JPWO2020154268 A5 JP WO2020154268A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nucleic acid
- angptl7
- position corresponding
- acid molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical class 0.000 claims 124
- 101000924546 Homo sapiens Angiopoietin-related protein 7 Proteins 0.000 claims 109
- 108020004707 nucleic acids Proteins 0.000 claims 103
- 102000039446 nucleic acids Human genes 0.000 claims 103
- 102100034598 Angiopoietin-related protein 7 Human genes 0.000 claims 102
- 239000002773 nucleotide Substances 0.000 claims 88
- 125000003729 nucleotide group Chemical group 0.000 claims 88
- 239000012472 biological sample Substances 0.000 claims 56
- 230000000295 complement effect Effects 0.000 claims 51
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims 48
- 108020004999 messenger RNA Proteins 0.000 claims 39
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 36
- 239000002299 complementary DNA Substances 0.000 claims 35
- 229930024421 Adenine Natural products 0.000 claims 34
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims 34
- 229960000643 adenine Drugs 0.000 claims 34
- 238000000034 method Methods 0.000 claims 27
- 238000012163 sequencing technique Methods 0.000 claims 27
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 24
- 229940113082 thymine Drugs 0.000 claims 24
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 21
- 238000003556 assay Methods 0.000 claims 21
- 238000003205 genotyping method Methods 0.000 claims 21
- 239000000523 sample Substances 0.000 claims 19
- 229940104302 cytosine Drugs 0.000 claims 18
- 230000035772 mutation Effects 0.000 claims 18
- 229940035893 uracil Drugs 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 108020005004 Guide RNA Proteins 0.000 claims 8
- 102000053528 human ANGPTL7 Human genes 0.000 claims 7
- 238000002372 labelling Methods 0.000 claims 5
- 239000004055 small Interfering RNA Substances 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 108091027967 Small hairpin RNA Proteins 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 208000030533 eye disease Diseases 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102220481839 Angiopoietin-related protein 7_Q175H_mutation Human genes 0.000 claims 1
- 108091033409 CRISPR Proteins 0.000 claims 1
- 108020004635 Complementary DNA Proteins 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 102220383610 c.906C>A Human genes 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 102200129548 rs119103287 Human genes 0.000 claims 1
- 102200078355 rs139300921 Human genes 0.000 claims 1
- 102220338990 rs1481765326 Human genes 0.000 claims 1
- 102200078354 rs41307846 Human genes 0.000 claims 1
- 102220240629 rs55968949 Human genes 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024213170A JP2025023307A (ja) | 2019-01-23 | 2024-12-06 | アンジオポエチン様７（ａｎｇｐｔｌ７）阻害剤による眼疾患の治療 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962795665P | 2019-01-23 | 2019-01-23 | |
| US62/795,665 | 2019-01-23 | ||
| US201962880609P | 2019-07-30 | 2019-07-30 | |
| US62/880,609 | 2019-07-30 | ||
| US201962902683P | 2019-09-19 | 2019-09-19 | |
| US62/902,683 | 2019-09-19 | ||
| US201962909573P | 2019-10-02 | 2019-10-02 | |
| US62/909,573 | 2019-10-02 | ||
| PCT/US2020/014373 WO2020154268A2 (en) | 2019-01-23 | 2020-01-21 | Treatment of ophthalmic conditions with angiopoietin-like 7 (angptl7) inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024213170A Division JP2025023307A (ja) | 2019-01-23 | 2024-12-06 | アンジオポエチン様７（ａｎｇｐｔｌ７）阻害剤による眼疾患の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022523301A JP2022523301A (ja) | 2022-04-22 |
| JPWO2020154268A5 true JPWO2020154268A5 (enExample) | 2023-01-30 |
Family
ID=69591771
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021543226A Pending JP2022523301A (ja) | 2019-01-23 | 2020-01-21 | アンジオポエチン様７（ａｎｇｐｔｌ７）阻害剤による眼疾患の治療 |
| JP2024213170A Pending JP2025023307A (ja) | 2019-01-23 | 2024-12-06 | アンジオポエチン様７（ａｎｇｐｔｌ７）阻害剤による眼疾患の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024213170A Pending JP2025023307A (ja) | 2019-01-23 | 2024-12-06 | アンジオポエチン様７（ａｎｇｐｔｌ７）阻害剤による眼疾患の治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11767526B2 (enExample) |
| EP (1) | EP3914711A2 (enExample) |
| JP (2) | JP2022523301A (enExample) |
| KR (1) | KR20210132045A (enExample) |
| CN (1) | CN113646432A (enExample) |
| AU (1) | AU2020210630B2 (enExample) |
| CA (1) | CA3126476A1 (enExample) |
| IL (1) | IL284700B2 (enExample) |
| MX (1) | MX2021008797A (enExample) |
| SG (1) | SG11202107497XA (enExample) |
| WO (1) | WO2020154268A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11845989B2 (en) | 2019-01-23 | 2023-12-19 | Regeneron Pharmaceuticals, Inc. | Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors |
| EP3914711A2 (en) | 2019-01-23 | 2021-12-01 | Regeneron Pharmaceuticals, Inc. | Treatment of ophthalmic conditions with angiopoietin-like 7 (angptl7) inhibitors |
| KR20220024153A (ko) | 2019-05-24 | 2022-03-03 | 엠피리코 인크. | 안지오포이에틴 유사 7(angptl7) 관련 질환의 치료 |
| US20230357774A1 (en) * | 2020-09-29 | 2023-11-09 | Empirico Inc. | Compositions and methods for the treatment of angiopoietin like 7 (angptl7) related diseases |
| EP4251753A4 (en) * | 2020-11-24 | 2025-08-06 | Empirico Inc | TREATMENT OF DISEASES AND DISORDERS RELATED TO SOS2 |
| WO2022182768A1 (en) * | 2021-02-26 | 2022-09-01 | Regeneron Pharmaceuticals, Inc. | Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (angptl7) inhibitors |
| JP2024535110A (ja) * | 2021-09-30 | 2024-09-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｒｈｏグアニンヌクレオチド交換因子１２（ＡＲＨＧＥＦ１２）阻害剤による緑内障の治療 |
| CA3241896A1 (en) * | 2021-12-22 | 2023-06-29 | Regeneron Pharmaceuticals, Inc. | Treatment of kidney diseases with angiopoietin like 3 (angptl3) inhibitors |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102895673A (zh) | 2004-08-23 | 2013-01-30 | 西伦蒂斯私人股份公司 | 眼病的治疗 |
| WO2008004719A1 (en) | 2006-07-05 | 2008-01-10 | Orientbio Co., Ltd | Method for diagnosing cancer by detecting the methylation of transitional zones |
| CN102482713B (zh) | 2009-05-11 | 2017-06-30 | 博格有限责任公司 | 利用表观代谢转变剂、多维细胞内分子或环境影响剂诊断肿瘤障碍的方法 |
| CN104530182A (zh) | 2009-07-27 | 2015-04-22 | 利普森技术有限公司 | 非凝血蛋白的糖基多唾液酸化 |
| US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| RU2595442C2 (ru) | 2009-07-27 | 2016-08-27 | Баксалта Инкорпорейтед | Конъюгаты белков свертывания крови |
| CA2769244A1 (en) | 2009-07-27 | 2011-02-03 | Lipoxen Technologies Limited | Glycopolysialylation of non-blood coagulation proteins |
| US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| US20130022983A1 (en) | 2009-10-26 | 2013-01-24 | Externautics S.P.A. | Colon and Rectal Tumor Markers and Methods of Use Thereof |
| NZ719474A (en) | 2010-01-11 | 2018-07-27 | Genomic Health Inc | Method to use gene expression to determine likelihood of clinical outcome of renal cancer |
| EP2397559A1 (en) | 2010-06-17 | 2011-12-21 | Max-Delbrück-Centrum Für Molekulare Medizin | Stage-specific biomarkers for the diagnosis of acute kidney injury |
| US20120010230A1 (en) | 2010-07-08 | 2012-01-12 | Macdougall John R | Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling |
| KR102325780B1 (ko) | 2010-07-30 | 2021-11-12 | 박스알타 인코퍼레이티드 | 옥심 결합용 친핵성 촉매 |
| BR112013015898A2 (pt) | 2010-12-22 | 2018-06-26 | Baxter International Inc. | derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada. |
| AU2012255066B2 (en) | 2011-05-18 | 2016-06-02 | Takeda Pharmaceutical Company Limited | Modification-dependent activity assays |
| CA2853823C (en) | 2011-10-28 | 2016-12-20 | Integritybio Inc. | Protein formulations containing amino acids |
| WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
| AU2013204754C1 (en) | 2012-05-16 | 2018-10-11 | Takeda Pharmaceutical Company Limited | Nucleophilic Catalysts for Oxime Linkage |
| US20130310546A1 (en) | 2012-05-16 | 2013-11-21 | Bater Healthcare Sa | Nucleophilic catalysts for oxime linkage and use of nmr analyses of the same |
| WO2013181438A2 (en) | 2012-05-30 | 2013-12-05 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for modulating pro-inflammatory immune response |
| EP2898092A1 (en) | 2012-09-21 | 2015-07-29 | Integragen | A new method for classification of liver samples and diagnosis of focal nodule dysplasia, hepatocellular adenoma, and hepatocellular carcinoma |
| US9206423B2 (en) | 2012-12-30 | 2015-12-08 | The Regents Of The University Of California | Methods of modulating compliance of the trabecular meshwork |
| WO2014167529A1 (en) | 2013-04-10 | 2014-10-16 | Institut De Cardiologie De Montreal | Methods and compositions for preventing and treating atherosclerosis |
| US10011837B2 (en) | 2014-03-04 | 2018-07-03 | Sylentis Sau | SiRNAs and their use in methods and compositions for the treatment and/or prevention of eye conditions |
| CA2948871A1 (en) | 2014-05-22 | 2015-11-26 | Fred Hutchinson Cancer Research Center | Lilrb2 and notch-mediated expansion of hematopoietic precursor cells |
| WO2017088018A1 (en) | 2015-11-24 | 2017-06-01 | Commonwealth Scientific And Industrial Research Organisation | Production of viruses in cell culture |
| WO2017088017A1 (en) | 2015-11-24 | 2017-06-01 | Commonwealth Scientific And Industrial Research Organisation | Production of viruses in avian eggs |
| EP3436049B1 (en) | 2016-03-31 | 2022-01-12 | Baylor Research Institute | Angiopoietin-like protein 8 (angptl8) |
| BR112019003124A2 (pt) * | 2016-08-19 | 2019-10-01 | Toolgen Incorporated | sistema regulador de angiogênse artificialmente engendrado |
| MA46089A (fr) * | 2016-08-30 | 2019-07-10 | Regeneron Pharma | Procédés de traitement de la résistance à l'insuline grave par interférence avec la signalisation du récepteur du glucagon |
| US12447213B2 (en) | 2016-10-07 | 2025-10-21 | The Broad Institute, Inc. | Modulation of novel immune checkpoint targets |
| CA3043223A1 (en) | 2016-11-14 | 2018-05-17 | Memorial Sloan-Kettering Cancer Center | Stem cell-derived schwann cells |
| WO2018174861A1 (en) | 2017-03-21 | 2018-09-27 | Mprobe Inc. | Methods and compositions for detecting early stage breast cancer with rna-seq expression profiling |
| EP3600108A4 (en) | 2017-03-23 | 2021-01-06 | The Regents of the University of California | STIMULATION OF HAIR GROWTH BY SENESCENT CELLS AND THE SECRETORY PHENOTYPE ASSOCIATED WITH SENESCENCE |
| JP6779164B2 (ja) * | 2017-03-28 | 2020-11-04 | ヤンマーパワーテクノロジー株式会社 | 作業車両の自律走行システム |
| JP2018164442A (ja) * | 2017-03-28 | 2018-10-25 | 国立大学法人 熊本大学 | 皮膚有棘細胞癌の判定、予防又は治療方法 |
| EP3630981A4 (en) | 2017-05-31 | 2021-03-03 | Commonwealth Scientific and Industrial Research Organisation | CHARACTERISTICS SELECTION IN BIRDS |
| US11485743B2 (en) | 2018-01-12 | 2022-11-01 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| EP3740224A4 (en) | 2018-01-18 | 2022-05-04 | Adanate, Inc. | ANTI-LILRB ANTIBODIES AND THEIR USES |
| GB201806118D0 (en) | 2018-04-13 | 2018-05-30 | Univ Edinburgh | Macrophage use |
| EP3914711A2 (en) | 2019-01-23 | 2021-12-01 | Regeneron Pharmaceuticals, Inc. | Treatment of ophthalmic conditions with angiopoietin-like 7 (angptl7) inhibitors |
| KR20220024153A (ko) | 2019-05-24 | 2022-03-03 | 엠피리코 인크. | 안지오포이에틴 유사 7(angptl7) 관련 질환의 치료 |
| US20230357774A1 (en) | 2020-09-29 | 2023-11-09 | Empirico Inc. | Compositions and methods for the treatment of angiopoietin like 7 (angptl7) related diseases |
-
2020
- 2020-01-21 EP EP20705596.3A patent/EP3914711A2/en active Pending
- 2020-01-21 CA CA3126476A patent/CA3126476A1/en active Pending
- 2020-01-21 AU AU2020210630A patent/AU2020210630B2/en active Active
- 2020-01-21 CN CN202080022870.2A patent/CN113646432A/zh active Pending
- 2020-01-21 SG SG11202107497XA patent/SG11202107497XA/en unknown
- 2020-01-21 KR KR1020217026590A patent/KR20210132045A/ko active Pending
- 2020-01-21 US US16/748,006 patent/US11767526B2/en active Active
- 2020-01-21 JP JP2021543226A patent/JP2022523301A/ja active Pending
- 2020-01-21 IL IL284700A patent/IL284700B2/en unknown
- 2020-01-21 WO PCT/US2020/014373 patent/WO2020154268A2/en not_active Ceased
- 2020-01-21 MX MX2021008797A patent/MX2021008797A/es unknown
-
2021
- 2021-05-12 US US17/318,023 patent/US11512309B2/en active Active
-
2024
- 2024-12-06 JP JP2024213170A patent/JP2025023307A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3693352B2 (ja) | プローブアレイを使用して、遺伝子多型性を検出し、対立遺伝子発現をモニターする方法 | |
| JP2008520242A5 (enExample) | ||
| KR20170015509A (ko) | 담도암 검출 키트 또는 디바이스 및 검출 방법 | |
| CN113046424B (zh) | 一种用于pcr检测的核酸组合物的制备方法及其制备的核酸组合物和pcr检测方法 | |
| JP2011505812A5 (enExample) | ||
| US11591646B2 (en) | Small RNA detection method based on small RNA primed xenosensor module amplification | |
| WO2008064519A1 (en) | Methods and compositions for diagnosis of esophageal cancer and prognosis and improvement of patient survival | |
| WO2016167317A1 (ja) | 遺伝子変異の検出方法 | |
| JPWO2020154268A5 (enExample) | ||
| CN105506156B (zh) | 诊断骨肉瘤的分子标志物 | |
| Greber-Platzer et al. | Evidence against the current hypothesis of “gene dosage effects” of trisomy 21: ets-2, encoded on chromosome 21” is not overexpressed in hearts of patients with Down syndrome | |
| JP5427352B2 (ja) | ヒト体脂肪量と関連する遺伝子多型に基づく肥満発症リスクの判定方法 | |
| JP2005507654A5 (enExample) | ||
| CN108676852B (zh) | 在外周血游离dna中检测p53基因表观遗传学修饰差异的引物对组及试剂盒 | |
| JP4145129B2 (ja) | Ｐｃｒクランピング法 | |
| JP5169306B2 (ja) | プロスタサイクリン受容体遺伝子のｓｎｐを利用した緑内障の発症リスクの判定方法 | |
| JP2022544393A (ja) | マクロファージ刺激１受容体（ｍｓｔ１ｒ）バリアント及びその使用 | |
| JPWO2020139830A5 (enExample) | ||
| RU2023131494A (ru) | Лечение цереброваскулярного заболевания с помощью агентов - белков-гомологов 3 нейрогенного локуса notch (notch3) | |
| RU2021121850A (ru) | Лечение офтальмологических патологических состояний ингибиторами ангиопоэтин-подобного белка 7 (angptl7) | |
| CN108251519B (zh) | 轴前多指病的致病基因及其用途 | |
| RU2021122161A (ru) | Лечение респираторных нарушений с помощью ингибиторов арахидонат 15-липоксигеназы (alox15) | |
| JP3002115B2 (ja) | ヒト急性および慢性を含む持続性ストレス負荷における細胞内ＨＳＰ７０ｍＲＮＡの転写異常とその応用（新規ヒト細胞内ＳＨＳＰ７０ｍＲＮＡの転写発現とＨＳＰ７０ｍＲＮＡ転写異常との応用） | |
| JPH08140699A (ja) | チロシナーゼｍＲＮＡ量の測定法 | |
| RU2021129890A (ru) | Лечение гипергликемии с помощью ингибиторов члена 5 семейства 39 транспортеров растворенных веществ (slc39a5) |